HK1148032A1 - Gene expression profiling in biopsied tumor tissues - Google Patents

Gene expression profiling in biopsied tumor tissues

Info

Publication number
HK1148032A1
HK1148032A1 HK11102089.5A HK11102089A HK1148032A1 HK 1148032 A1 HK1148032 A1 HK 1148032A1 HK 11102089 A HK11102089 A HK 11102089A HK 1148032 A1 HK1148032 A1 HK 1148032A1
Authority
HK
Hong Kong
Prior art keywords
gene expression
tumor tissues
breast cancer
expression profiling
biopsied tumor
Prior art date
Application number
HK11102089.5A
Inventor
Joffre B Baker
Maureen T Cronin
Michael C Kiefer
Steve Shak
Michael G Walker
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28045456&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1148032(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Publication of HK1148032A1 publication Critical patent/HK1148032A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention concerns sensitive methods to measure mRNA levels in biopsied tumor tissues, including archived paraffin-embedded biopsy material. The invention also concerns breast cancer gene sets important in the diagnosis and treatment of breast cancer, and methods for assigning the most optimal treatment options to breast cancer patient based upon knowledge derived for gene expression studies.
HK11102089.5A 2002-03-13 2008-11-07 Gene expression profiling in biopsied tumor tissues HK1148032A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36489002P 2002-03-13 2002-03-13
US41204902P 2002-09-18 2002-09-18

Publications (1)

Publication Number Publication Date
HK1148032A1 true HK1148032A1 (en) 2011-08-26

Family

ID=28045456

Family Applications (4)

Application Number Title Priority Date Filing Date
HK11102089.5A HK1148032A1 (en) 2002-03-13 2008-11-07 Gene expression profiling in biopsied tumor tissues
HK11102091.1A HK1148034A1 (en) 2002-03-13 2008-11-07 Gene expression profiling in biopsied tumor tissues
HK08112262.8A HK1120567A1 (en) 2002-03-13 2008-11-07 Gene expression profiling in biopsied tumor tissues
HK15104243.0A HK1203568A1 (en) 2002-03-13 2015-05-04 Gene expression profiling in biopsied tumor tissues

Family Applications After (3)

Application Number Title Priority Date Filing Date
HK11102091.1A HK1148034A1 (en) 2002-03-13 2008-11-07 Gene expression profiling in biopsied tumor tissues
HK08112262.8A HK1120567A1 (en) 2002-03-13 2008-11-07 Gene expression profiling in biopsied tumor tissues
HK15104243.0A HK1203568A1 (en) 2002-03-13 2015-05-04 Gene expression profiling in biopsied tumor tissues

Country Status (10)

Country Link
US (9) US7081340B2 (en)
EP (9) EP2258872B1 (en)
JP (6) JP2005519624A (en)
AT (1) ATE529535T1 (en)
AU (1) AU2003253986A1 (en)
CA (2) CA2992643C (en)
DK (5) DK1918386T3 (en)
ES (5) ES2685702T3 (en)
HK (4) HK1148032A1 (en)
WO (1) WO2003078662A1 (en)

Families Citing this family (221)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972697A (en) * 1995-11-13 1999-10-26 The Salk Institute For Biological Studies NIMA interacting proteins
US7125677B2 (en) * 1995-11-13 2006-10-24 The Salk Institute For Biological Studies NIMA interacting proteins
US6277566B1 (en) * 1998-02-13 2001-08-21 Phillip A. Beachy Method for identifying a hedgehog-mediated phosphorylation state dependent transcription factor
US20080085515A1 (en) * 2000-03-24 2008-04-10 Eppendorf Array Technologies Sa (Eat) Identification of multiple biological (micro) organisms by detection of their nucleotide sequences on arrays
US20070298423A1 (en) * 2000-03-24 2007-12-27 Eppendorf Array Technologies Sa (Eat) Identification of multiple biological (micro) organisms by specific amplification and detection of their nucleotide sequences on arrays
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US7640484B2 (en) 2001-12-28 2009-12-29 Netapp, Inc. Triple parity technique for enabling efficient recovery from triple failures in a storage array
EP2258872B1 (en) * 2002-03-13 2013-08-14 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US7364846B2 (en) * 2002-10-11 2008-04-29 Molecular Devices Corporation Gene expression profiling from FFPE samples
WO2004046386A1 (en) 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
US20050266409A1 (en) * 2003-02-04 2005-12-01 Wyeth Compositions and methods for diagnosing, preventing, and treating cancers
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
US20050064455A1 (en) * 2003-05-28 2005-03-24 Baker Joffre B. Gene expression markers for predicting response to chemotherapy
JP4871722B2 (en) † 2003-07-25 2012-02-08 アプライド バイオシステムズ リミテッド ライアビリティー カンパニー Methods and compositions for preparing RNA from fixed samples
DE10344799A1 (en) * 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy
FR2861744A1 (en) * 2003-11-05 2005-05-06 Biomerieux Sa METHOD FOR THE PROGNOSIS OF BREAST CANCER
WO2005064019A2 (en) * 2003-12-23 2005-07-14 Genomic Health, Inc. Universal amplification of fragmented rna
US20100190150A1 (en) * 2004-01-07 2010-07-29 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
US20050221398A1 (en) * 2004-01-16 2005-10-06 Ipsogen, Sas, A Corporation Of France Protein expression profiling and breast cancer prognosis
US20070270488A1 (en) * 2004-03-12 2007-11-22 The Queen's University Of Belfast Treatment and Assays
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
JP5813908B2 (en) 2004-04-09 2015-11-17 ジェノミック ヘルス， インコーポレイテッド Gene expression markers to predict response to chemotherapeutic agents
US20120258442A1 (en) 2011-04-09 2012-10-11 bio Theranostics, Inc. Determining tumor origin
MXPA06014116A (en) * 2004-06-04 2007-08-08 Aviaradx Inc Identification of tumors.
JP2008505644A (en) * 2004-07-09 2008-02-28 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション Identification of markers in esophageal cancer, colon cancer, head and neck cancer, and melanoma
DE102004042822A1 (en) * 2004-08-31 2006-03-16 Technische Universität Dresden Compounds and methods of treatment, diagnosis and prognosis in pancreatic diseases
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
AU2005300688B2 (en) * 2004-11-03 2012-02-02 Almac Diagnostics Limited Transcriptome microarray technology and methods of using the same
JP4939425B2 (en) 2004-11-05 2012-05-23 ジェノミック ヘルス， インコーポレイテッド Molecular indicators of prognosis and prediction of treatment response in breast cancer
EP1836629B1 (en) * 2004-11-05 2020-03-04 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
US8535914B2 (en) * 2005-01-21 2013-09-17 Canon Kabushiki Kaisha Probe, probe set and information acquisition method using the same
WO2006101925A2 (en) * 2005-03-16 2006-09-28 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US8383357B2 (en) 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
JP2008534002A (en) * 2005-04-01 2008-08-28 エヌシィーシィー テクノロジー ベンチャーズ ピィーティーイー．リミテッド Materials and methods for classification of breast cancer
WO2006108048A1 (en) * 2005-04-05 2006-10-12 The General Hospital Corporation Method for predicting responsiveness to drugs
US20060275844A1 (en) * 2005-04-19 2006-12-07 Linke Steven P Diagnostic markers of breast cancer treatment and progression and methods of use thereof
EP1899484B1 (en) 2005-06-03 2015-08-12 bioTheranostics, Inc. Identification of tumors and tissues
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US7700299B2 (en) * 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
CA2620195A1 (en) * 2005-08-24 2007-03-01 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
EP1931802A2 (en) * 2005-09-09 2008-06-18 The Board of Regents of The University of Texas System A calculated index of genomic expression of estrogen receptor (er) and er related genes
US20070071762A1 (en) * 2005-09-21 2007-03-29 Ccc Diagnostics, Llc Comprehensive diagnostic testing procedures for personalized anticancer chemotherapy (pac)
EP1945754B1 (en) 2005-10-31 2014-07-23 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2007067500A2 (en) * 2005-12-05 2007-06-14 Genomic Health, Inc. Predictors of patient response to treatment with egfr inhibitors
CA2633754C (en) * 2006-01-05 2013-06-18 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis and treatment of solid cancers
WO2007081387A1 (en) 2006-01-11 2007-07-19 Raindance Technologies, Inc. Microfluidic devices, methods of use, and kits for performing diagnostics
RU2436098C2 (en) 2006-02-09 2011-12-10 Юниверсити Оф Саут Флорида Cancer detection by high bcl-2 levels
WO2007123772A2 (en) 2006-03-31 2007-11-01 Genomic Health, Inc. Genes involved in estrogen metabolism
CN101240331A (en) * 2006-04-07 2008-08-13 甄二真 Skin beauty treatment health care method based on mEPHX gene polymorphism
WO2007127458A2 (en) * 2006-04-28 2007-11-08 Nsabp Foundation, Inc. Methods of whole genome or microarray expression profiling using nucleic acids
US20080003142A1 (en) 2006-05-11 2008-01-03 Link Darren R Microfluidic devices
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
EP3399450A1 (en) 2006-05-18 2018-11-07 Caris MPI, Inc. System and method for determining individualized medical intervention for a disease state
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
US20080050739A1 (en) * 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
WO2007147074A2 (en) 2006-06-14 2007-12-21 Living Microsystems, Inc. Use of highly parallel snp genotyping for fetal diagnosis
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
EP2589668A1 (en) 2006-06-14 2013-05-08 Verinata Health, Inc Rare cell analysis using sample splitting and DNA tags
EP2041574B1 (en) * 2006-07-14 2016-11-16 The Regents of The University of California Cancer biomarkers and methods of use threof
WO2008021123A1 (en) 2006-08-07 2008-02-21 President And Fellows Of Harvard College Fluorocarbon emulsion stabilizing surfactants
US20080118576A1 (en) * 2006-08-28 2008-05-22 Dan Theodorescu Prediction of an agent's or agents' activity across different cells and tissue types
WO2008030735A2 (en) * 2006-09-06 2008-03-13 Janssen Pharmaceutical N.V. Biomarkers for assessing response to c-met treatment
US7615349B2 (en) * 2006-09-07 2009-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
EP2081950B1 (en) * 2006-09-21 2013-03-20 Nuclea Biomarkers LLC Expression profiles associated with irinotecan treatment
JP5041580B2 (en) * 2006-10-17 2012-10-03 一般財団法人化学及血清療法研究所 Mediating polynucleotide
US20080125358A1 (en) * 2006-10-26 2008-05-29 University Of Massachusetts Medical School Methods for Chk2 inhibitor patient selection
KR100862972B1 (en) 2006-10-30 2008-10-13 한국과학기술연구원 Biomaker and screening method of volatile organic compounds having toxicity using thereof
WO2008063521A2 (en) * 2006-11-13 2008-05-29 The General Hospital Corporation Gene-based clinical scoring system
KR100886670B1 (en) 2007-01-11 2009-03-04 김현기 Novel proliferation marker in papillary thyroid carcinoma and novel method of diagnosis detecting the marker
US8148147B2 (en) 2007-01-24 2012-04-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
US8772046B2 (en) 2007-02-06 2014-07-08 Brandeis University Manipulation of fluids and reactions in microfluidic systems
JP5240739B2 (en) 2007-04-13 2013-07-17 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー Biological markers that predict anticancer responses to kinase inhibitors
KR20090128474A (en) * 2007-04-13 2009-12-15 브리스톨-마이어스 스큅 컴퍼니 Biomarkers and methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators
US8592221B2 (en) 2007-04-19 2013-11-26 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
WO2008150937A2 (en) * 2007-05-29 2008-12-11 Aivaradx, Inc. Real-time pcr
EP2167683A4 (en) 2007-05-31 2010-10-20 California Pacific Med Center Method to predict or diagnose a gastrointestinal disorder or disease
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
SI2171090T1 (en) 2007-06-08 2013-07-31 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
EP2167521A4 (en) 2007-06-15 2011-11-23 Univ Ohio State Res Found ONCOGENIC ALL-1 FUSION PROTEINS FOR TARGETING DROSHA-MEDIATED microRNA PROCESSING
US8883440B2 (en) 2007-07-26 2014-11-11 Nancy M. Lee Method to predict or diagnose a gastrointestinal disorder or disease
AU2008283997B2 (en) 2007-08-03 2014-04-10 The Ohio State University Research Foundation Ultraconserved regions encoding ncRNAs
EP2191020A2 (en) * 2007-08-16 2010-06-02 Genomic Health, Inc. Gene expression markers of recurrence risk in cancer patients after chemotherapy
EP2028600B1 (en) 2007-08-24 2016-10-26 Sysmex Corporation Diagnosis support system for cancer, diagnosis support for information providing method for cancer, and computer program product
US9388457B2 (en) 2007-09-14 2016-07-12 Affymetrix, Inc. Locus specific amplification using array probes
WO2009036427A2 (en) * 2007-09-14 2009-03-19 Ventana Medical Systems, Inc. Prostate cancer biomarkers
US8716190B2 (en) 2007-09-14 2014-05-06 Affymetrix, Inc. Amplification and analysis of selected targets on solid supports
CA2694356A1 (en) 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2009045361A2 (en) 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2009048901A1 (en) * 2007-10-09 2009-04-16 University Of Washington Quantitative/semi-quantitative measurement of epor on cancer cells
ES2538362T3 (en) 2007-10-16 2015-06-19 Ventana Medical Systems, Inc. Classification, staging and prognosis of cancer through the use of osteopontin-C
WO2009055559A1 (en) * 2007-10-23 2009-04-30 University Of South Florida Method of predicting chemotherapeutic responsiveness of cancer
US8911998B2 (en) 2007-10-26 2014-12-16 The Ohio State University Methods for identifying fragile histidine triad (FHIT) interaction and uses thereof
EP2065473A1 (en) * 2007-11-28 2009-06-03 Siemens Healthcare Diagnostics GmbH A method to assess prognosis and to predict therapeutic success in gynecologic cancer
WO2009068423A2 (en) 2007-11-30 2009-06-04 Siemens Healthcare Diagnostics Gmbh Method for predicting therapy responsiveness in basal like tumors
WO2009075799A2 (en) * 2007-12-05 2009-06-18 The Wistar Institute Of Anatomy And Biology Method for diagnosing lung cancers using gene expression profiles in peripheral blood mononuclear cells
US10416162B2 (en) 2007-12-20 2019-09-17 Monogram Biosciences, Inc. Her2 diagnostic methods
ES2482692T3 (en) 2008-05-12 2014-08-04 Genomic Health, Inc. Tests to predict the receptivity of cancer patients to chemotherapy treatment options
EP2288727B1 (en) * 2008-05-14 2013-07-10 Genomic Health, Inc. Predictors of patient response to treatment with egf receptor inhibitors
US20110318732A1 (en) * 2008-05-28 2011-12-29 Singer Robert H Prediction of chemotherapeutic response via single-cell profiling of transcription site activation
CN102149827B (en) 2008-06-11 2014-08-20 由卫生与公众服务部代表的***合众国政府 Use of MiR-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy
BRPI0812682A2 (en) 2008-06-16 2010-06-22 Genentech Inc metastatic breast cancer treatment
EP4047367A1 (en) 2008-07-18 2022-08-24 Bio-Rad Laboratories, Inc. Method for detecting target analytes with droplet libraries
EP3216874A1 (en) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
US10359425B2 (en) * 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
LT2334812T (en) 2008-09-20 2017-04-25 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US9782565B2 (en) 2008-10-01 2017-10-10 Covidien Lp Endoscopic ultrasound-guided biliary access system
US9332973B2 (en) 2008-10-01 2016-05-10 Covidien Lp Needle biopsy device with exchangeable needle and integrated needle protection
US9186128B2 (en) 2008-10-01 2015-11-17 Covidien Lp Needle biopsy device
US8968210B2 (en) 2008-10-01 2015-03-03 Covidien LLP Device for needle biopsy with integrated needle protection
US11298113B2 (en) 2008-10-01 2022-04-12 Covidien Lp Device for needle biopsy with integrated needle protection
US20100221752A2 (en) * 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
EP2347009A4 (en) * 2008-10-14 2012-05-30 Caris Mpi Inc Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
EP2342355A4 (en) * 2008-10-29 2012-06-27 Beaumont Hospital William Methods of using biomarkers
EP3181705A1 (en) 2008-11-12 2017-06-21 Caris Life Sciences Switzerland Holdings GmbH Methods and systems of using exosomes for determining phenotypes
WO2011109440A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings Biomarkers for theranostics
EP2438442B1 (en) 2008-12-01 2017-08-09 Laboratory Corporation of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
CN102460152B (en) 2009-01-15 2014-11-26 美国控股实验室公司 Methods of determining patient response by measurement of her-3
AU2010204576A1 (en) * 2009-01-15 2011-09-01 Laboratory Corporation Of America Holdings Methods of determining patient response by measurement of HER-2 expression
JP2012519170A (en) * 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー INSITU method for monitoring EMT status of tumor cells in vivo
US8528589B2 (en) 2009-03-23 2013-09-10 Raindance Technologies, Inc. Manipulation of microfluidic droplets
US20100311601A1 (en) * 2009-05-01 2010-12-09 Nuvera Biosciences, Inc. Index of genomic expression of estrogen receptor (er) and er-related genes
WO2010135411A2 (en) * 2009-05-19 2010-11-25 The Regents Of The University Of Colorado Aurora-a copy number and sensitivity to inhibitors
EP2278026A1 (en) * 2009-07-23 2011-01-26 Université de la Méditerranée A method for predicting clinical outcome of patients with breast carcinoma
WO2011031877A1 (en) 2009-09-09 2011-03-17 The General Hospital Corporation Use of microvesicles in analyzing nucleic acid profiles
US8563261B2 (en) 2009-09-28 2013-10-22 The Trustees Of The University Of Pennsylvania Method of diagnosing and treating interstitial cystitis
EP2486409A1 (en) 2009-10-09 2012-08-15 Universite De Strasbourg Labelled silica-based nanomaterial with enhanced properties and uses thereof
US7736861B1 (en) * 2009-10-19 2010-06-15 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
AU2010321555B2 (en) 2009-11-23 2015-10-15 The Ohio State University Materials and methods useful for affecting tumor cell growth, migration and invasion
MX337650B (en) * 2009-11-23 2016-03-14 Genomic Health Inc Methods to predict clinical outcome of cancer.
US20110129822A1 (en) * 2009-12-01 2011-06-02 Precision Therapeutics, Inc. Multi drug response markers for breast cancer cells
US10837883B2 (en) 2009-12-23 2020-11-17 Bio-Rad Laboratories, Inc. Microfluidic systems and methods for reducing the exchange of molecules between droplets
DK3178944T3 (en) * 2010-01-11 2019-08-12 Genomic Health Inc METHOD OF APPLYING GENE EXPRESSION TO DETERMINE THE LIKELIHOOD OF A CLINICAL RESULT OF NON-RISK
US20130011393A1 (en) * 2010-01-12 2013-01-10 Johnathan Mark Lancaster Bad pathway gene signature
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
EP2534267B1 (en) 2010-02-12 2018-04-11 Raindance Technologies, Inc. Digital analyte analysis
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
WO2011107819A1 (en) * 2010-03-01 2011-09-09 Adelbio Methods for predicting outcome of breast cancer, and/or risk of relapse, response or survival of a patient suffering therefrom
US20110217297A1 (en) * 2010-03-03 2011-09-08 Koo Foundation Sun Yat-Sen Cancer Center Methods for classifying and treating breast cancers
WO2011109584A2 (en) * 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US8444573B2 (en) 2010-03-30 2013-05-21 Siteselect Medical Technologies, Inc. Tissue excision device
KR101346955B1 (en) * 2010-03-30 2014-01-02 서울대학교산학협력단 Composition for predicting the recurrence possibility and survival prognosis of brain tumor and kit comprising the same
JP5553661B2 (en) 2010-03-30 2014-07-16 シスメックス株式会社 Cancer recurrence risk assessment method
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
EP2564200B8 (en) * 2010-04-27 2019-10-02 The Regents of The University of California Cancer biomarkers and methods of use thereof
CA2800684A1 (en) * 2010-05-26 2011-12-01 Expression Pathology, Inc. Urokinase-type plasminogen activator protein/plasminogen activator inhibitor type-1 protein selected reaction monitoring assay
WO2012006447A2 (en) 2010-07-07 2012-01-12 Myriad Genetics, Inc. Gene signatures for cancer prognosis
CN104777313B (en) 2010-07-09 2017-09-26 私募蛋白质体公司 Lung cancer biomarkers and application thereof
DE102010033575B4 (en) 2010-08-02 2016-01-14 Eberhard-Karls-Universität Tübingen Universitätsklinikum ASPP2 splice variant
EP2603622A4 (en) 2010-08-13 2015-04-22 Somalogic Inc Pancreatic cancer biomarkers and uses thereof
CA2809829A1 (en) 2010-08-30 2012-03-08 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
US9562897B2 (en) 2010-09-30 2017-02-07 Raindance Technologies, Inc. Sandwich assays in droplets
CA2816603A1 (en) 2010-11-12 2012-05-18 The Ohio State University Research Foundation Materials and methods related to microrna-21, mismatch repair, and colorectal cancer
CN103313706A (en) 2010-11-15 2013-09-18 俄亥俄州立大学研究基金会 Controlled release mucoadhesive systems
WO2012090073A2 (en) * 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
WO2012097368A2 (en) * 2011-01-14 2012-07-19 Response Genetics, Inc. Her3 and her4 primers and probes for detecting her3 and her4 mrna expression
WO2012109233A2 (en) * 2011-02-07 2012-08-16 Board Of Regents, The University Of Texas System Methods for predicting recurrence risk in breast cancer patients
WO2012109600A2 (en) 2011-02-11 2012-08-16 Raindance Technologies, Inc. Methods for forming mixed droplets
EP3736281A1 (en) 2011-02-18 2020-11-11 Bio-Rad Laboratories, Inc. Compositions and methods for molecular labeling
AU2012225506B2 (en) 2011-03-07 2016-11-17 The Ohio State University Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
US9556470B2 (en) 2011-06-02 2017-01-31 Raindance Technologies, Inc. Enzyme quantification
EP2726609A4 (en) * 2011-07-01 2015-03-04 Pinpoint Genomics Inc Method for extracting rna from fixed embedded tissue
WO2013010074A1 (en) 2011-07-13 2013-01-17 Primeradx, Inc. Multimodal methods for simultaneous detection and quantification of multiple nucleic acids in a sample
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
GB201114919D0 (en) * 2011-08-30 2011-10-12 Glaxosmithkline Biolog Sa Method
CN102533740B (en) * 2011-09-07 2013-07-24 杭州艾迪康医学检验中心有限公司 Reverse transcription-polymerase chain reaction (RT-PCR) primer of human leukemia fusion gene BCR-ABL and application method thereof
WO2013056217A1 (en) 2011-10-14 2013-04-18 The Ohio State University Methods and materials related to ovarian cancer
EP2776830B1 (en) * 2011-11-08 2018-05-09 Genomic Health, Inc. Method of predicting breast cancer prognosis
CN103145845A (en) * 2011-12-06 2013-06-12 吉林圣元科技有限责任公司 Expression of Tat and human wild-type P53 fusion protein in Pichia pastoris
CN104619353A (en) 2011-12-13 2015-05-13 俄亥俄州国家创新基金会 Methods and compositions related to miR-21 and miR-29a, exosome inhibition, and cancer metastasis
JP2015511121A (en) * 2012-01-20 2015-04-16 ジ・オハイオ・ステート・ユニバーシティ Breast cancer biomarker signature for invasiveness and prognosis
WO2013120089A1 (en) 2012-02-10 2013-08-15 Raindance Technologies, Inc. Molecular diagnostic screening assay
WO2013165748A1 (en) 2012-04-30 2013-11-07 Raindance Technologies, Inc Digital analyte analysis
US20140038838A1 (en) 2012-06-27 2014-02-06 Niven Rajin Narain Use of markers in the diagnosis and treatment of prostate cancer
WO2014078700A1 (en) 2012-11-16 2014-05-22 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US20140186468A1 (en) * 2012-12-07 2014-07-03 Susana Gonzalo Diagnosing subsets of triple-negative breast cancer
KR20150107738A (en) 2013-01-18 2015-09-23 엘리스 클라인 Selective glycosidase regimen for immune programming and treatment of cancer
JP6576249B2 (en) 2013-02-11 2019-09-18 インクロン， インコーポレイテッド Use of chromatin transcription factor (FACT) in cancer
WO2014172288A2 (en) 2013-04-19 2014-10-23 Raindance Technologies, Inc. Digital analyte analysis
CA2912786A1 (en) 2013-05-21 2014-11-27 Dignity Health Genetic signature of vulnerability to inhibitors of base excision repair (ber) in cancer
JP2016521979A (en) 2013-05-30 2016-07-28 ジェノミック ヘルス， インコーポレイテッド Gene expression profiling algorithm for calculating recurrence score for patients with kidney cancer
WO2015048098A1 (en) 2013-09-24 2015-04-02 Washington University Diagnostic methods for infectious disease using endogenous gene expression
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
WO2015103367A1 (en) 2013-12-31 2015-07-09 Raindance Technologies, Inc. System and method for detection of rna species
CA2947624A1 (en) 2014-05-13 2015-11-19 Myriad Genetics, Inc. Gene signatures for cancer prognosis
CN106795557A (en) 2014-06-02 2017-05-31 瓦利保健***公司 For the method and system of pulmonary cancer diagnosis
US9994912B2 (en) 2014-07-03 2018-06-12 Abbott Molecular Inc. Materials and methods for assessing progression of prostate cancer
WO2016059195A1 (en) * 2014-10-17 2016-04-21 Assistance Publique Hopitaux De Paris Methods for the monitoring and prognosis of a cancer
DK3210142T3 (en) 2014-10-24 2020-11-16 Koninklijke Philips Nv ASSESSMENT OF TGF CELLULAR SIGNALING VEHICLE ACTIVITY USING MATHEMATICAL MODELING OF MOAL EXPRESSION
EP3210143B1 (en) 2014-10-24 2020-12-09 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
ES2838923T3 (en) 2014-10-24 2021-07-02 Koninklijke Philips Nv Medical prognosis and prediction of response to treatment using multiple activities of the cell signaling pathway
EP3227687A4 (en) 2014-12-05 2018-10-24 Prelude, Inc. Dcis recurrence and invasive breast cancer
WO2016094425A1 (en) 2014-12-08 2016-06-16 Berg Llc Use of markers including filamin a in the diagnosis and treatment of prostate cancer
CA2995586A1 (en) 2015-08-06 2017-02-09 The Wistar Institute Of Anatomy And Biology Combination therapies targeting mitochondrial biogenesis for cancer therapy
CA2995520A1 (en) 2015-08-14 2017-02-23 Hendrik Jan VAN OOIJEN Assessment of nfkb cellular signaling pathway activity using mathematical modelling of target gene expression
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
KR20190026769A (en) 2016-06-21 2019-03-13 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 Compositions and methods for diagnosing lung cancer using gene expression profiles
US10487365B2 (en) 2016-09-20 2019-11-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for detecting expression of lnc-FANCI-2 in cervical cells
WO2018093797A1 (en) * 2016-11-15 2018-05-24 The Schepens Eye Research Institute, Inc. Compositions and methods for the treatment of aberrant angiogenesis
KR101950717B1 (en) * 2016-11-23 2019-02-21 주식회사 젠큐릭스 Methods for predicting effectiveness of chemotherapy for breast cancer patients
US10636512B2 (en) 2017-07-14 2020-04-28 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs
EP3461915A1 (en) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression
AU2018369784B2 (en) 2017-11-14 2023-06-01 Massachusetts Eye And Ear Infirmary RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
EP3502279A1 (en) 2017-12-20 2019-06-26 Koninklijke Philips N.V. Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression
CN110045120A (en) * 2018-01-15 2019-07-23 长庚医疗财团法人基隆长庚纪念医院 Detect detection kit and its application of the concentration of WISP1 in biological sample in preparation for breast cancer screening and detecting recurrence
WO2020056162A1 (en) * 2018-09-12 2020-03-19 Oregon Health & Science University Detecting and/or subtyping circulating hybrid cells that correlate with stage and survival
AU2019339508A1 (en) 2018-09-14 2021-04-15 Prelude Corporation Method of selection for treatment of subjects at risk of invasive breast cancer
WO2020178399A1 (en) 2019-03-05 2020-09-10 Norwegian University Of Science And Technology (Ntnu) Breast cancer signature genes
WO2021154146A1 (en) * 2020-01-30 2021-08-05 Arocell Ab Predicting patient survival
BR112023021762A2 (en) * 2021-04-21 2023-12-26 Apollomics Inc DIAGNOSIS AND TREATMENT OF CANCER USING C-MET INHIBITOR
EP4253567A1 (en) * 2022-03-31 2023-10-04 OncoAssure Limited A method of predicting risk of an aggressive or recurrent cancer

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US788019A (en) * 1904-06-29 1905-04-25 Charlie B Cady Hay fork and hook.
USRE35491E (en) 1982-11-04 1997-04-08 The Regents Of The University Of California Methods and compositions for detecting human tumors
IE56509B1 (en) 1982-11-04 1991-08-28 Univ California Methods for oncogenic detection
US4699877A (en) * 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
US7838216B1 (en) * 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5015568A (en) 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US5831066A (en) 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US6316208B1 (en) * 1994-01-07 2001-11-13 Memorial Sloan-Kettering Cancer Center Methods for determining isolated p27 protein levels and uses thereof
US5563035A (en) * 1994-06-16 1996-10-08 The Board Of Trustees Of The Leland Stanford Junior University Estrogen receptor regulation and its uses
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
US5858678A (en) 1994-08-02 1999-01-12 St. Louis University Apoptosis-regulating proteins
CA2262403C (en) 1995-07-31 2011-09-20 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US5821082A (en) * 1996-05-23 1998-10-13 St. Louis University Health Sciences Center Anti-proliferation domain of a human Bcl-2 and DNA encoding the same
US5846723A (en) * 1996-12-20 1998-12-08 Geron Corporation Methods for detecting the RNA component of telomerase
AU724107B2 (en) * 1997-01-31 2000-09-14 Fred Hutchinson Cancer Research Center Prognosis of cancer patients by determining expression of cell cycle regulators p27 and cyclin E
JP2001525673A (en) * 1997-05-15 2001-12-11 トーマス ジェファーソン ユニバーシティ Determination of cyclin-dependent kinase inhibitor P27 level as a prognostic factor in cancer patients
WO1999002714A1 (en) 1997-07-07 1999-01-21 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
WO1999064626A2 (en) * 1998-06-06 1999-12-16 Genostic Pharma Limited Probes used for genetic profiling
AU2342900A (en) * 1998-09-23 2000-05-01 Cleveland Clinic Foundation, The Novel interferon stimulated and repressed genes
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
AU3246200A (en) 1999-02-25 2000-09-14 Boris Bilynsky Nucleic acid molecules associated with melanoma and thyroid tumors
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
AU3752700A (en) * 1999-03-15 2000-10-04 Eos Biotechnology, Inc. Novel methods of diagnosing and treating breast cancer, compositions, and methods of screening for breast cancer modulators
US6647341B1 (en) * 1999-04-09 2003-11-11 Whitehead Institute For Biomedical Research Methods for classifying samples and ascertaining previously unknown classes
US6960439B2 (en) * 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
JP2003504073A (en) * 1999-07-09 2003-02-04 ザ バーナム インスティチュート Method for determining the prognosis of a cancer patient by measuring the level of BAG expression
US6326148B1 (en) 1999-07-12 2001-12-04 The Regents Of The University Of California Detection of copy number changes in colon cancer
US6271002B1 (en) 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
WO2001025250A1 (en) 1999-10-06 2001-04-12 The Regents Of The University Of California Differentially expressed genes associated with her-2/neu overexpression
US6703202B2 (en) * 1999-11-30 2004-03-09 Oxo Chemie Ag Evaluating and predicting clinical outcomes by gene expression analysis
AU2055401A (en) 1999-12-01 2001-06-12 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6750013B2 (en) 1999-12-02 2004-06-15 Protein Design Labs, Inc. Methods for detection and diagnosing of breast cancer
US6248535B1 (en) 1999-12-20 2001-06-19 University Of Southern California Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens
EP1276901A2 (en) * 2000-01-13 2003-01-22 Amsterdam Support Diagnostics B.V. A universal nucleic acid amplification system for nucleic acids in a sample
DK1246917T3 (en) * 2000-01-13 2009-06-08 Genentech Inc Human Stra6 polypeptides
US6322986B1 (en) * 2000-01-18 2001-11-27 Albany Medical College Method for colorectal cancer prognosis and treatment selection
US6618679B2 (en) * 2000-01-28 2003-09-09 Althea Technologies, Inc. Methods for analysis of gene expression
AU2001241418A1 (en) 2000-01-31 2001-08-07 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU4592601A (en) 2000-03-21 2001-10-03 Millennium Predictive Medicine Novel genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer
US6759197B2 (en) * 2000-03-31 2004-07-06 Sir Mortimer B. Davis -- Jewish General Hospital Microchip arrays of regulatory genes
WO2002000677A1 (en) 2000-06-07 2002-01-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
MXPA03000575A (en) * 2000-07-21 2004-12-13 Global Genomics Ab Methods for analysis and identification of transcribed genes, and fingerprinting.
US7118853B2 (en) 2000-07-26 2006-10-10 Applied Genomics, Inc. Methods of classifying, diagnosing, stratifying and treating cancer patients and their tumors
WO2002008260A2 (en) 2000-07-26 2002-01-31 Stanford University Bstp-ecg1 protein and related reagents and methods of use thereof
US6388073B1 (en) 2000-07-26 2002-05-14 Shire Us Inc. Method for the manufacture of anagrelide
AU2001277202A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-ras/rerg protein and related reagents and methods of use thereof
WO2002010436A2 (en) * 2000-07-28 2002-02-07 The Brigham And Women's Hospital, Inc. Prognostic classification of breast cancer
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
US20030018079A1 (en) * 2000-11-13 2003-01-23 Richardson Helene Treatment
US6602670B2 (en) * 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US6582919B2 (en) * 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
AU2002234799A1 (en) 2000-12-08 2002-06-18 Ipsogen Gene expression profiling of primary breast carcinomas using arrays of candidate genes
WO2002068579A2 (en) 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
AU2002245317A1 (en) 2001-01-24 2002-08-06 Protein Design Labs Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
US20070015148A1 (en) * 2001-01-25 2007-01-18 Orr Michael S Gene expression profiles in breast tissue
US20030199685A1 (en) * 2001-03-12 2003-10-23 Monogen, Inc. Cell-based detection and differentiation of disease states
US20020194022A1 (en) * 2001-04-06 2002-12-19 Florence Comite System and method for delivering integrated health care
EP1399593A2 (en) * 2001-05-16 2004-03-24 Novartis AG Genes expressed in breast cancer as prognostic and therapeutic targets
JP2005500832A (en) * 2001-06-18 2005-01-13 ロゼッタ・インファーマティクス・インコーポレーテッド Diagnosis and prognosis of breast cancer patients
AU2002322280A1 (en) * 2001-06-21 2003-01-21 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2003011897A1 (en) 2001-07-27 2003-02-13 The Regents Of The University Of California Modulation of heregulin and her3 interaction
US20040009489A1 (en) * 2001-09-28 2004-01-15 Golub Todd R. Classification of lung carcinomas using gene expression analysis
EP2258872B1 (en) * 2002-03-13 2013-08-14 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
EP1492871A2 (en) 2002-03-28 2005-01-05 QLT Inc. Cancer associated protein kinases and their uses
EP1900827A3 (en) 2002-05-21 2008-04-16 Bayer HealthCare AG Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia
WO2004000094A2 (en) 2002-06-19 2003-12-31 Smithkline Beecham Corporation Predictive markers in cancer therapy
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
CA2516553C (en) * 2003-02-20 2013-04-16 Genomic Health, Inc. Use of intronic rna to measure gene expression
US20050064455A1 (en) * 2003-05-28 2005-03-24 Baker Joffre B. Gene expression markers for predicting response to chemotherapy
EP3170906B1 (en) * 2003-06-24 2018-08-22 Genomic Health, Inc. Prediction of likelihood of cancer recurrence
DK1644858T3 (en) * 2003-07-10 2018-01-22 Genomic Health Inc Functional clothing with at least one outer layer and inner membrane.
US20050221398A1 (en) * 2004-01-16 2005-10-06 Ipsogen, Sas, A Corporation Of France Protein expression profiling and breast cancer prognosis
JP5813908B2 (en) * 2004-04-09 2015-11-17 ジェノミック ヘルス， インコーポレイテッド Gene expression markers to predict response to chemotherapeutic agents
JP2006040014A (en) 2004-07-28 2006-02-09 Matsushita Electric Ind Co Ltd Information communication terminal
WO2006015312A2 (en) * 2004-07-30 2006-02-09 Rosetta Inpharmatics Llc Prognosis of breast cancer patients
JP4939425B2 (en) * 2004-11-05 2012-05-23 ジェノミック ヘルス， インコーポレイテッド Molecular indicators of prognosis and prediction of treatment response in breast cancer
EP1836629B1 (en) * 2004-11-05 2020-03-04 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
CA2613290A1 (en) * 2005-05-27 2007-05-24 Aurelium Biopharma Inc. Focused microarray and methods of diagnosing chemotherapeutic drug resistance in a cancer cell
WO2006138275A2 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
JP4369419B2 (en) * 2005-12-09 2009-11-18 株式会社小松製作所 Guided travel control device for unmanned vehicles
WO2007123772A2 (en) 2006-03-31 2007-11-01 Genomic Health, Inc. Genes involved in estrogen metabolism
WO2007121014A1 (en) * 2006-04-11 2007-10-25 Sensortran, Inc. Methods and apparatus for calibrating distributed fiber temperature sensing system
US7569645B2 (en) * 2007-06-27 2009-08-04 Momentive Performance Materials Inc. Curable silyl-containing polymer composition containing paint adhesion additive
EP2191020A2 (en) * 2007-08-16 2010-06-02 Genomic Health, Inc. Gene expression markers of recurrence risk in cancer patients after chemotherapy
ES2482692T3 (en) * 2008-05-12 2014-08-04 Genomic Health, Inc. Tests to predict the receptivity of cancer patients to chemotherapy treatment options

Also Published As

Publication number Publication date
AU2003253986A8 (en) 2003-09-29
EP2258873A2 (en) 2010-12-08
AU2003253986A1 (en) 2003-09-29
EP2799555B1 (en) 2017-02-22
EP2261369A3 (en) 2011-05-04
EP1918386B1 (en) 2011-10-19
EP1918386A1 (en) 2008-05-07
EP1918386A9 (en) 2008-07-09
US7858304B2 (en) 2010-12-28
US20030225528A1 (en) 2003-12-04
US20070141589A1 (en) 2007-06-21
EP2241636A1 (en) 2010-10-20
US20080182255A1 (en) 2008-07-31
EP2261369B1 (en) 2014-05-14
JP4753741B2 (en) 2011-08-24
ES2685702T3 (en) 2018-10-10
ES2486265T3 (en) 2014-08-18
EP1918386B9 (en) 2012-08-08
EP2258873A3 (en) 2011-05-04
JP2006129880A (en) 2006-05-25
JP5461730B2 (en) 2014-04-02
JP2013146278A (en) 2013-08-01
DK2258872T3 (en) 2013-11-18
ATE529535T1 (en) 2011-11-15
JP2013146277A (en) 2013-08-01
WO2003078662A9 (en) 2007-09-27
EP2258872B1 (en) 2013-08-14
EP3115470B1 (en) 2018-07-18
HK1120567A1 (en) 2009-04-03
DK2261369T3 (en) 2014-07-28
CA2478850A1 (en) 2003-09-25
JP5792765B2 (en) 2015-10-14
DK1918386T3 (en) 2012-01-02
EP1488007A1 (en) 2004-12-22
JP2011250809A (en) 2011-12-15
EP2261369A2 (en) 2010-12-15
WO2003078662A1 (en) 2003-09-25
JP2013146279A (en) 2013-08-01
US7081340B2 (en) 2006-07-25
US10241114B2 (en) 2019-03-26
CA2478850C (en) 2018-02-27
US20070065846A1 (en) 2007-03-22
EP2258872A2 (en) 2010-12-08
ES2374311T3 (en) 2012-02-15
DK3115470T3 (en) 2018-11-05
JP2005519624A (en) 2005-07-07
US20070141587A1 (en) 2007-06-21
JP5373019B2 (en) 2013-12-18
CA2992643C (en) 2019-06-18
EP1488007A4 (en) 2006-05-03
US7838224B2 (en) 2010-11-23
EP2261368A1 (en) 2010-12-15
US20070059737A1 (en) 2007-03-15
US20070141588A1 (en) 2007-06-21
EP2258872A3 (en) 2011-05-04
US8071286B2 (en) 2011-12-06
CA2992643A1 (en) 2003-09-25
EP3115470A1 (en) 2017-01-11
ES2433992T3 (en) 2013-12-13
ES2616800T3 (en) 2017-06-14
JP5461729B2 (en) 2014-04-02
US20070065845A1 (en) 2007-03-22
EP2799555A1 (en) 2014-11-05
HK1203568A1 (en) 2015-10-30
US20100209920A1 (en) 2010-08-19
DK2799555T3 (en) 2017-05-22
HK1148034A1 (en) 2011-08-26

Similar Documents

Publication Publication Date Title
HK1203568A1 (en) Gene expression profiling in biopsied tumor tissues
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
HK1148783A1 (en) Gene expression markers for breast cancer prognosis
WO2003042661A8 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
IL182423A0 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
WO2003106974A3 (en) Diagnosis and treatment of chemoresistant tumors
EP1590433A4 (en) Diagnosis and prognosis of breast cancer patients
MXPA05005923A (en) Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy.
WO2006133325A3 (en) Analysis of tissue samples surrounding malignancies
WO2003087831A3 (en) Proteins involved in breast cancer
WO2005040421A3 (en) Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues
AU2002251366A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2004073657A3 (en) Methods of diagnosis of cancer and other diseases, composition and methods of screening for modulators of cancer and other diseases
AU2003217397A8 (en) Claudins, markers for diagnosis, prognosis and therapy of breast, bone, brain cancer
ATE458049T1 (en) GENE EXPRESSED IN PROSTATE CANCER
MXPA05014220A (en) Genes regulated in ovarian cancer as prognostic and therapeutic targets.
AU2001240909A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2005065361A3 (en) Compounds and compositions for treating dysproliferative diseases, and methods of use thereof
HK1056692A1 (en) Proteins
CA2435320A1 (en) Compositions and methods for the use of fibronectin fragments in the diagnosis of cancer
WO2003083102A3 (en) Cancer associated protein phosphatases and their uses
WO2001055450A3 (en) AMPLIFIED GENES AT 17q23
WO2003076651A3 (en) Cancer associated araf1 protein kinase and its uses
WO2003020294A8 (en) Aromatase marking
AU2003282069A8 (en) Tumor marker proteins for diagnosis and therapy of cancer and cancer risk assessment

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20230311